Status:

COMPLETED

Tolerability of ALK Grass Tablet in Children

Lead Sponsor:

ALK-Abelló A/S

Conditions:

Allergy

Eligibility:

All Genders

5-12 years

Phase:

PHASE1

Brief Summary

The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years

Eligibility Criteria

Inclusion

  • Grass pollen induced rhinoconjunctivitis
  • Boys and girls, 5-12 years of age
  • Positive skin prick test to grass pollen

Exclusion

  • Severe asthma
  • Previous treatment with immunotherapy

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00310453

Start Date

March 1 2006

End Date

May 1 2006

Last Update

May 4 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Servicio de Alergia, Hospital del Niño Jesús

Madrid, Spain, 28040